This CME/CE activity is derived from content presented at the 6th Annual Advanced Curriculum for Multiple Sclerosis 2021 Virtual CME/CE Course. The expert faculty, led by Dr. Fred D. Lublin, will review the science and mode of action for Bruton’s Tyrosine Kinase (BTK) inhibitors. The faculty will analyze the role of BTK in microglia and the clinical trial data on novel brain-penetrant BTK inhibitors to block microglia-driven neuroinflammation implicated in multiple sclerosis (MS) disease progression. Additionally, a review on how to develop patient-focused treatment strategies that reduce disability and prevent disease progression in patients with multiple sclerosis will be discussed. The faculty will conclude with an interactive expert panel discussion, delving into the new and emerging role of BTK inhibitor therapeutics to help improve long-term outcomes in patients with relapsing MS.
Neurologists, MS specialists, nurse practitioners, physicians’ assistants, nurses, and pharmacists who comprise the comprehensive MS care team, as well as other healthcare professionals involved in the management of patients with multiple sclerosis
- Understand the science and mode of action for BTK inhibitors
- Evaluate the role of BTK in microglia and clinical trial data on novel brain-penetrant BTK inhibitors to block microglia-driven neuroinflammation implicated in MS disease progression
- Develop patient-focused treatment strategies that reduce disability and prevent disease progression in patients with MS
I. The Science of BTK Inhibitors for the Management of Multiple Sclerosis – Benjamin Greenberg, MD
II. A Clinical Trial Analysis of the Efficacy, Safety, and Tolerability Data for Latest Therapeutic Advances Including BTK Inhibitors – Anthony Traboulsee, MD
III. MS Treatment Plans: Where will BTK Fit into Treatment Strategies – Aaron Miller, MD
IV. Interactive Expert Panel Discussion – Fred D. Lublin, MD and Expert Faculty
Benjamin M. Greenberg, MD, MHS
Vice Chair of Translational Research
Department of Neurology and Neurotherapeutics
Director, Neuroimmunology Programs
UT Southwestern Medical Center
Children’s Medical Center
Anthony Traboulsee, MD
Professor, Department of Neurology
University of British Columbia
MS Society of Canada Research Chair
Director, MS Clinical Trials Research Group
Assistant Director, Multiple Sclerosis/Magnetic Resonance Imaging Research Group
Vancouver, British Columbia, Canada
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
Fred D. Lublin, MD
|Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals Ltd; Apitope; Atara Biotherapeutics, Inc.; Avotres Inc.; Biogen; BrainStorm Cell Limited; Celgene Corporation; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Greenwich Biosciences, a GW Pharmaceuticals PLC Company; Immunic Therapeutics; Innate Immunotherapeutics; Janssen Global Services, LLC; Jazz Pharmaceuticals, Inc.; Mapi-Pharma Ltd.; MedDay Pharmaceuticals; MedImmune Pharma; Mylan; Novartis AG; Orion Biotechnology; Polpharma; Population Council; Receptos; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; Viela Bio
Grant/Research Support: Actelion Pharmaceuticals Ltd; Biogen; BrainStorm Cell Limited; Novartis AG; Sanofi Genzyme
Speaker’s Bureau: Sanofi Genzyme
Benjamin M. Greenberg, MD, MHS
|Consultant/Advisor: Alexion Pharmaceuticals, Inc.; EMD Serono, Inc.; Genentech, Inc.; Novartis AG; Sandoz International GmbH; Viela Bio
Grant/Research Support: Anokion SA; Clene Nanomedicine, Inc.
Aaron Miller, MD
|Consultant/Advisor: AbbVie Inc.; Accordant, A CVS Caremark Company; Adamas Pharmaceuticals, Inc.; Biogen; Bristol-Myers Squibb; Celgene Corporation; Corrona, LLC; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Janssen Global Services, LLC; Mapi-Pharma Ltd.; Mylan; Novartis AG; Verana Health
Grant/Research Support: F. Hoffmann-La Roche Ltd; Genentech, Inc.; Mallinckrodt Pharmaceuticals; MedDay Pharmaceuticals; Novartis AG; Sanofi Genzyme
Speakers Bureau: Alexion Pharmaceuticals, Inc.; Biogen; EMD Serono, Inc.; Genentech, Inc.
Anthony Traboulsee, MD
|Consultant/Advisor: Biogen; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Novartis AG; Sanofi Genzyme
Grant/Research Support: Sanofi Genzyme; Roche
Speaker’s Bureau: EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Sanofi Genzyme
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; John Fanikos, RPh; Amy Perrin Ross, APN, MSN, CNRN, MSCN; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour.
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (JA4008190-0000-21-005-H04-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from EMD Serono
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and EMD Serono do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].